Pafolacianine received FDA approval on November 29, 2021. This approval has provided surgeons with a novel tool to enhance the visualization of ovarian cancer lesions, thereby improving surgical outcomes.

Maribavir received FDA approval on November 23, 2021. This approval provides a new treatment option for post-transplant patients dealing with refractory CMV infections.

Sirolimus was approved by the U.S. Food and Drug Administration (FDA) on September 15, 1999.

Asciminib was approved by the U.S. Food and Drug Administration (FDA) on October 29, 2021.

celecoxib and tramadol, marketed under the brand name Seglentis, received FDA approval on October 15, 2021.

Maralixibat, marketed under the brand name Livmarli, received FDA approval on September 29, 2021.

atogepant is FDA approved. Atogepant, marketed under the brand name Qulipta, received FDA approval on September 28, 2021.

Tisotumab vedotin (Tivdak) received accelerated approval from the US Food and Drug Administration (FDA) on September 20, 2021.

Mobocertinib (Exkivity) received accelerated approval from the US Food and Drug Administration (FDA) on September 15, 2021.

Lonapegsomatropin (Skytrofa) received FDA approval on August 25, 2021.

The U.S. Food and Drug Administration (FDA) approved Difelikefalin on August 23, 2021, for the treatment of moderate-to-severe pruritus (itching) associated with chronic kidney disease in adults undergoing hemodialysis (HD).

The U.S. Food and Drug Administration (FDA) approved Belzutifan on August 13, 2021, for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC).